Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
On November 2, we published the Q3 Interim Report. Below, Nikolaj Sørensen, CEO, summarizes the quarter and what he looks forward to in 2024:
Presentation of the Interim Report Q3 2023
Extraordinary General Meeting on October 26
Read the protocol from the EGM under Corporate Governance - EGM
Latest CEO Comments
NOVEMBER 2, 2023
"Approaching EBITDA in balance H2"
Read the latest CEO comments from Nikolaj Sørensen
Key financial figures
Group net revenue
629 MSEK
Last Twelve Months, Q422-Q323
Group EBITDA
-98 MSEK
Last Twelve Months, Q422-Q323
US Pharma segment EBIT
285 MSEK
Last Twelve Months, Q422-Q323
Cash position
184 MSEK
Q323
News flow
Press Releases and News
Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose
Orexo announces changes in the company´s Board of Directors
Invitation to the presentation of Orexo´s Q3 2023 Interim Report
Orexo´s Nomination Committee for the Annual General Meeting 2024
